HRP20031000A2 - Benzoylsulfonamides and sulfonylbenzamidines as antitumour agents - Google Patents

Benzoylsulfonamides and sulfonylbenzamidines as antitumour agents

Info

Publication number
HRP20031000A2
HRP20031000A2 HR20031000A HRP20031000A HRP20031000A2 HR P20031000 A2 HRP20031000 A2 HR P20031000A2 HR 20031000 A HR20031000 A HR 20031000A HR P20031000 A HRP20031000 A HR P20031000A HR P20031000 A2 HRP20031000 A2 HR P20031000A2
Authority
HR
Croatia
Prior art keywords
sulfonylbenzamidines
benzoylsulfonamides
antitumour agents
antitumour
agents
Prior art date
Application number
HR20031000A
Other languages
English (en)
Inventor
Thomas Hughes Corbett
Cora Sue Grossman
Karen Lynn Lobb
Chuan Shih
Philip Arthur Hipskind
Ho-Shen Lin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HRP20031000A2 publication Critical patent/HRP20031000A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C07D213/34—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Furan Compounds (AREA)
HR20031000A 2001-06-06 2003-12-03 Benzoylsulfonamides and sulfonylbenzamidines as antitumour agents HRP20031000A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29635001P 2001-06-06 2001-06-06
PCT/US2002/015142 WO2002098848A1 (en) 2001-06-06 2002-05-24 Benzoylsulfonamides and sulfonylbenzamidines for use as antitumour agents

Publications (1)

Publication Number Publication Date
HRP20031000A2 true HRP20031000A2 (en) 2004-04-30

Family

ID=23141662

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20031000A HRP20031000A2 (en) 2001-06-06 2003-12-03 Benzoylsulfonamides and sulfonylbenzamidines as antitumour agents

Country Status (36)

Country Link
US (1) US7183320B2 (de)
EP (1) EP1401806B1 (de)
JP (1) JP4167173B2 (de)
KR (1) KR100880760B1 (de)
CN (1) CN100475787C (de)
AR (1) AR036079A1 (de)
AT (1) ATE335722T1 (de)
AU (1) AU2002259204B2 (de)
BR (1) BR0210078A (de)
CA (1) CA2446719A1 (de)
CR (1) CR7182A (de)
CY (1) CY1105386T1 (de)
CZ (1) CZ20033296A3 (de)
DE (1) DE60213810T2 (de)
DK (1) DK1401806T3 (de)
EA (1) EA005810B1 (de)
EC (1) ECSP034874A (de)
EG (1) EG24356A (de)
ES (1) ES2269688T3 (de)
HK (1) HK1064360A1 (de)
HR (1) HRP20031000A2 (de)
HU (1) HUP0400114A3 (de)
IL (1) IL158985A0 (de)
MX (1) MXPA03011197A (de)
MY (1) MY136855A (de)
NO (1) NO20035366L (de)
NZ (1) NZ529098A (de)
PE (1) PE20030199A1 (de)
PL (1) PL367188A1 (de)
PT (1) PT1401806E (de)
SK (1) SK14642003A3 (de)
SV (1) SV2003001076A (de)
TW (1) TWI266761B (de)
UA (1) UA74889C2 (de)
WO (1) WO2002098848A1 (de)
ZA (1) ZA200308644B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60316984T2 (de) 2002-11-22 2008-07-17 Eli Lilly And Co., Indianapolis Benzoylsulfonamide als antitumor-mittel
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
EP1765778B1 (de) * 2004-05-26 2012-01-25 Abbott Laboratories N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP2364699A1 (de) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Gemeinsame Verwendung einer sulfonamidbasierten Verbindung mit Angiogenesehemmer
JP5134247B2 (ja) * 2004-09-13 2013-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド含有化合物の血管新生阻害物質との併用
WO2006090932A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Managemant Co., Ltd. スルホンアミド化合物の代理マーカー
SI1859793T1 (sl) * 2005-02-28 2011-08-31 Eisai R&D Man Co Ltd Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
KR20070114774A (ko) * 2005-02-28 2007-12-04 에자이 알앤드디 매니지먼트 가부시키가이샤 술폰아미드 화합물의 혈관 신생 저해 물질과의 신규 병용
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
PT1888550E (pt) 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Promotores de apoptose
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
US7208506B2 (en) 2005-07-07 2007-04-24 Hoffmann-La Roche Inc. Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
US7625896B2 (en) * 2005-11-25 2009-12-01 Hoffman-La Roche Inc. Pyridylsulfonamide derivatives
JPWO2007123274A1 (ja) 2006-04-20 2009-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の新規感受性マーカー
CN101534904B (zh) 2006-09-05 2013-11-06 Abbvie公司 治疗血小板过量的bcl抑制剂
US7939532B2 (en) 2006-10-26 2011-05-10 Hoffmann-La Roche Inc. Heterocyclyl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
CA2686768A1 (en) * 2007-05-16 2008-11-20 F. Hoffmann-La Roche Ag Aryl pyridyl sulfonamide derivatives, their manufacture and use as pharmaceutical agents
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
NZ593593A (en) * 2009-01-19 2013-11-29 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2012136435A (ja) * 2009-03-30 2012-07-19 Eisai R & D Management Co Ltd 腫瘍組織の感受性を検査する方法
KR200457823Y1 (ko) * 2009-05-08 2012-01-05 황정용 쭈꾸미 포획용 어구
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
HUE027698T2 (en) 2009-05-26 2016-10-28 Abbvie Bahamas Ltd Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2550258B1 (de) * 2010-03-25 2015-08-19 Abbvie Inc. Apoptoseinduktoren für die behandlung von krebs sowie immun- und autoimmunerkrankungen
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
JP6141188B2 (ja) 2010-11-23 2017-06-07 アッヴィ・インコーポレイテッド アポトーシス誘導剤の塩および結晶の形態
MY191300A (en) 2010-11-23 2022-06-14 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
CN103159649B (zh) * 2011-12-19 2016-03-09 天津市国际生物医药联合研究院 磺酰胺类化合物的制备及其应用
CN103159650B (zh) * 2011-12-19 2016-04-20 天津市国际生物医药联合研究院 芳香杂环磺酰胺类化合物的制备及其应用
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN105712925B (zh) * 2014-12-05 2019-01-04 沈阳中化农药化工研发有限公司 一种取代的磺酰胺基(硫代)羰基化合物及其用途
CN107257789B (zh) 2015-02-13 2021-06-29 牛津药物设计有限公司 作为氨酰-trna合成酶抑制剂的新型n-酰基-芳基磺酰胺衍生物
CN105753748B (zh) * 2016-02-15 2018-05-29 南京励合化学新材料有限公司 一种医药中间体磺酰类化合物的合成方法
GB201617064D0 (en) 2016-10-07 2016-11-23 Inhibox Limited And Latvian Institute Of Organic Synthesis The Compounds and their therapeutic use
US11479532B2 (en) * 2017-06-23 2022-10-25 University Of South Florida 5-aminolevulinate synthase inhibitors and methods of use thereof
KR20200094215A (ko) * 2017-12-29 2020-08-06 공윈 바이오팜 컴퍼니, 리미티드 (타이완) 벤젠술폰아미드 유도체 및 지질 래프트 조정 방법
CN114790149A (zh) * 2021-01-26 2022-07-26 江苏中旗科技股份有限公司 一种以2-氯-4-氟苯胺为原料合成2-氯-4-氟苯甲酸的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4157257A (en) 1976-10-01 1979-06-05 Utsunomiya University Benzenesulfonamide derivatives
US4266078A (en) * 1979-04-20 1981-05-05 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
US4347380A (en) * 1979-04-20 1982-08-31 Stauffer Chemical Company N-Acylsulfonamide herbicidal antidotes
US4433997A (en) * 1979-04-20 1984-02-28 Stauffer Chemical Co N-Acylsulfonamide herbicidal antidotes
US4495365A (en) * 1980-11-21 1985-01-22 Stauffer Chemical Co. N-Acylsulfonamide herbicidal antidotes
US5110830A (en) * 1984-06-27 1992-05-05 Eli Lilly And Company Benzenesulfonamides treatment of tumors susceptible to
US4845128A (en) * 1984-06-27 1989-07-04 Eli Lilly And Company N([(4-trifluoromethylphenyl)amino]carbonyl)benzene sulfonamides
JP2679498B2 (ja) * 1991-12-25 1997-11-19 王子製紙株式会社 感熱記録体
CA2110524A1 (en) * 1992-12-10 1994-06-11 Gerald Burr Grindey Antitumor compositions and methods of treatment
JPH0747772A (ja) * 1993-08-05 1995-02-21 New Oji Paper Co Ltd 感熱記録体
US5728712A (en) 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
ATE230275T1 (de) * 1995-10-25 2003-01-15 Senju Pharma Co Angiogense-inhibitor
US5929097A (en) 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
AU2879300A (en) * 1999-02-12 2000-08-29 Cellpath, Inc. Methods for anti-tumor therapy
AR031130A1 (es) 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US20020055631A1 (en) 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
US6720338B2 (en) 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters

Also Published As

Publication number Publication date
ECSP034874A (es) 2004-01-28
CR7182A (es) 2004-06-08
CA2446719A1 (en) 2002-12-12
ZA200308644B (en) 2005-02-07
US7183320B2 (en) 2007-02-27
CZ20033296A3 (cs) 2004-04-14
WO2002098848A1 (en) 2002-12-12
PE20030199A1 (es) 2003-03-12
HUP0400114A2 (hu) 2005-04-28
AR036079A1 (es) 2004-08-11
PL367188A1 (en) 2005-02-21
SK14642003A3 (sk) 2004-12-01
MXPA03011197A (es) 2004-02-26
HUP0400114A3 (en) 2007-05-02
PT1401806E (pt) 2006-11-30
US20040157741A1 (en) 2004-08-12
EP1401806B1 (de) 2006-08-09
UA74889C2 (en) 2006-02-15
DE60213810T2 (de) 2007-02-01
ATE335722T1 (de) 2006-09-15
AU2002259204B2 (en) 2008-01-17
EA005810B1 (ru) 2005-06-30
KR100880760B1 (ko) 2009-02-02
KR20040007656A (ko) 2004-01-24
JP2004530709A (ja) 2004-10-07
BR0210078A (pt) 2004-06-22
DK1401806T3 (da) 2006-11-27
DE60213810D1 (de) 2006-09-21
CN1514824A (zh) 2004-07-21
NZ529098A (en) 2005-08-26
EP1401806A1 (de) 2004-03-31
CY1105386T1 (el) 2010-04-28
NO20035366D0 (no) 2003-12-02
EG24356A (en) 2009-03-04
NO20035366L (no) 2004-02-06
ES2269688T3 (es) 2007-04-01
HK1064360A1 (en) 2005-01-28
JP4167173B2 (ja) 2008-10-15
TWI266761B (en) 2006-11-21
MY136855A (en) 2008-11-28
EA200400006A1 (ru) 2004-06-24
IL158985A0 (en) 2004-05-12
SV2003001076A (es) 2003-07-29
CN100475787C (zh) 2009-04-08

Similar Documents

Publication Publication Date Title
HRP20031000A2 (en) Benzoylsulfonamides and sulfonylbenzamidines as antitumour agents
EP1463742A4 (de) Neue pyrazolo- und pyrrolo-pyrimidine und ihre verwendungszwecke
IL159918A0 (en) Secretion-monitoring article
EP1408978A4 (de) Neue phenylamino-pyrimidine und ihre verwendungszwecke
IL157845A0 (en) Anti-epileptogenic agents
IL154553A0 (en) Urocortin-iii and uses thereof
PT1419268E (pt) Artigo de monitorização de secreção
GB0123657D0 (en) Worktool
GB2376928B (en) Personal hoverplane having four tiltmotors
DE60226167D1 (en) Computersystem-e/a-knoten
DE60223825D1 (en) Ethynylierungsverfahren
GB0126889D0 (en) Compounds and their uses
IL160539A0 (en) Anti-influenzal agents
EP1408985A4 (de) Neue pyridopyrimidone und ihre verwendungszwecke
GB0102319D0 (en) Light-diffuser
DE60206072D1 (en) Aroylpyridinone
EP1367123A4 (de) Neurotonin und dessen verwendung
GB0106031D0 (en) Use
GB0106987D0 (en) Immunotherapeuitic agent
GB0122162D0 (en) Agent
GB0113275D0 (en) Fishing-tackle article
GB0106600D0 (en) Addition circuitry
GB0003629D0 (en) Antitumour agent
HU0100486D0 (en) Bolyhos spirit
GB0120289D0 (en) V place

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODBC Application rejected